Overview

Location [1]
7q21.2
Pathway
Cell cycle control
Protein [2]
Cyclin-dependent kinase 6
Synonyms [1]
PLSTIRE, MCPH12

Cyclin-dependent kinase 4 (CDK6) is a gene that encodes a protein that is a member of the cyclin-dependent protein kinase family. The protein functions in the progression of the cell cycle at from G1 to S phase and the regulation of RB1. Fusions, missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

CDK6 is altered in 0.96% of all cancers with non-small cell lung carcinoma, malignant glioma, breast carcinoma, colorectal adenocarcinoma, and melanoma having the greatest prevalence of alterations [3].

CDK6 GENIE Cases - Top Diseases

The most common alterations in CDK6 are CDK6 Amplification (0.55%), CDK6 Mutation (0.39%), CDK6 Loss (0.02%), CDK6 R220C (0.01%), and CDK6 I159M (0.01%) [3].

CDK6 GENIE Cases - Top Alterations

Significance of CDK6 in Diseases

Malignant Solid Tumor +

Multiple Myeloma +

Non-Hodgkin Lymphoma +

Head And Neck Squamous Cell Carcinoma +

Breast Carcinoma +

Lymphoma +

Esophageal Carcinoma +

Gastric Carcinoma +

Malignant Glioma +

Colorectal Carcinoma +

Squamous Cell Lung Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Cancer +

Chordoma +

Germ Cell Tumor +

Histiocytic And Dendritic Cell Neoplasm +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.